Cargando…

Use of Tocilizumab in patients with stable chronic liver disease and severe COVID-19 for prevention of decompensated cirrhosis, a prospective, open-label, randomized controlled trial.

Detalles Bibliográficos
Autores principales:	Rosales Renteria, Luis Alejandro, Jaramillo-Ramírez, Hiram, Calderón-Mendieta, Francisco, Camacho-Escobedo, Jesús, Avendaño-Reyes, José Manuel, López-Rubio, Diana Laura, Araiza, Adrián Sández, Reyes-Higuera, Gisel Estefania, Soto-González, Dulce Renée, Arzola-Renteria, Erikc Jesús
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association for the Study of the Liver. Published by Elsevier B.V. 2022
Materias:	POSTER PRESENTATIONS: Thursday 23 June: Cirrhosis and its complications: ACLF and Critical illness
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252357/ http://dx.doi.org/10.1016/S0168-8278(22)01067-4

Ejemplares similares

COVID-19 in patients with cirrhosis: insights from the multinational LEOSS registry
por: Brozat, Jonathan Frederik, et al.
Publicado: (2022)

SARS-CoV-2 infection in patients with underlying chronic liver disease is associated with significantly greater risks of inpatient hospitalization, intensive care unit admission, and overall mortality
por: Wong, Robert, et al.
Publicado: (2022)

Bile duct‐ligated mice exhibit multiple phenotypic similarities to acute decompensation patients despite histological differences
por: O'Brien, Alastair, et al.
Publicado: (2015)

Renin/angiotensin system-coagulation-inflammation axis abnormalities: a possible explanation for susceptibility to severe COVID-19 in cirrhosis
por: Hartl, Lukas, et al.
Publicado: (2022)

Patients with decompensated cirrhosis and liver transplant recipients demonstrate poor humoral and cellular immune response against COVID-19 vaccine
por: Kulkarni, Anand, et al.
Publicado: (2022)

Impact of the COVID-19 pandemic on the incidence and type of infections in hospitalized patients with cirrhosis
por: Cuyas, Berta, et al.
Publicado: (2022)

Humoral, cellular, clinical responses and safety to SARS-CoV-2 messanger RNA vaccines in patients with compensated and decompensated cirrhosis: a long-term single center prospective study
por: Iavarone, Massimo, et al.
Publicado: (2022)

Presence of cirrhosis in chronic liver disease patients associates with a lower immune response to COVID-19 vaccines-a multicenter european study
por: Simão, André L., et al.
Publicado: (2022)

COVID-19 vaccination in liver cirrhosis: safety and immune and clinical responses
por: Canha, Maria Ines, et al.
Publicado: (2022)

Humoral and cellular immunity after vaccination against SARS-CoV-2 is reduced in patients with chronic liver disease
por: Samer, Al-Dury, et al.
Publicado: (2022)

Heterologous SARS-CoV-2 vaccine triggers more humoral immune responses among patients with liver cirrhosis
por: Kaewdech, Apichat, et al.
Publicado: (2022)

Enhancing the cascade of hepatitis C care in community-recruited high-risk people who inject drugs during the COVID-19 pandemic: the Alexandros program
por: Sypsa, Vana, et al.
Publicado: (2022)

Knowledge, attitude and practice regarding COVID-19 vaccination among HCV infected patients in Georgia
por: Gulbiani, Lasha, et al.
Publicado: (2022)

mRNA COVID-19 vaccine effectiveness in liver transplant patients
por: Khan, Muhammad, et al.
Publicado: (2022)

Assessment of COVID-19 impact and response on hepatitis B virus and hepatitis C virus prevention and treatment from nationwide survey in Japan
por: Ashraf Hussain, Md Razeen, et al.
Publicado: (2022)

A novel prognostic model including liver function parameters accurately predicts 30-day mortality in patients admitted with COVID-19
por: Lee, David Uihwan, et al.
Publicado: (2022)

Effectiveness of mRNA vaccines in patients with cirrhosis with rising prevalence of SARS-CoV-2 delta variant
por: John, Binu, et al.
Publicado: (2022)

Prognostic value of liver function test for COVID-19 hospitalized patients with respiratory disease
por: Mateu, Carlos Alventosa, et al.
Publicado: (2022)

Effectiveness of COVID-19 viral vector vaccine Ad.26.COV2.S vaccine and comparison with mRNA vaccines in patients with cirrhosis
por: John, Binu, et al.
Publicado: (2022)

Implementation of HCV screening in the 1969–1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy
por: D’Ambrosio, Roberta, et al.
Publicado: (2022)

No effect of HBsAg positivity on antibody response after COVID-19 vaccine
por: Jargalsaikhan, Ganbolor, et al.
Publicado: (2022)

The prognostic implications of liver function test abnormalities in patients admitted to hospital with COVID-19
por: Cohen, Jason, et al.
Publicado: (2022)

Evaluation of immune response and disease flares in metobolic-associated fatty liver disease patients following SARS-CoV-2 vaccination: a prospective cohort study
por: Shi, Junping, et al.
Publicado: (2022)

Combined COVID-19 vaccination and HIV and hepatitis C virus screening intervention for high-risk populations at a mobile testing unit in Madrid, Spain
por: Valencia, Jorge, et al.
Publicado: (2022)

The impact of COVID-19 pandemic control measures on HCV treatment initiation in British Columbia, Canada
por: Janjua, Naveed, et al.
Publicado: (2022)

Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease
por: Younossi, Zobair, et al.
Publicado: (2022)

Association between immunosuppressants and poor antibody responses to inactivated SARS-CoV-2 vaccines in patients with autoimmune liver diseases
por: Li, Hu, et al.
Publicado: (2022)

Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis
por: Lehmann, Jennifer, et al.
Publicado: (2019)

Durability of immune response to SARS-CoV-2 vaccination in patients with liver cirrhosis (LC) as compared to healthcare workers (HW)
por: Mangia, Alessandra, et al.
Publicado: (2022)

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2018)

Non-infective complications for people living with HIV
por: Chenciner, Louisa, et al.
Publicado: (2022)

COVID-19 pandemic impact on alcoholic hepatitis healthcare utilisation
por: Nedumannil, Leya, et al.
Publicado: (2022)

Increased hospital admissions for alcohol-associated hepatitis during the COVID-19 pandemic in Alberta, Canada: a retrospective cohort study
por: Frolkis, Alexandra, et al.
Publicado: (2022)

Trends of alcohol-related liver disease hospitalisation during the COVID-19 pandemic
por: Ayonrinde, Oyekoya, et al.
Publicado: (2022)

Implementation of a ‘care bundle’ improves the management of patients admitted to hospital with decompensated cirrhosis
por: Dyson, J. K., et al.
Publicado: (2016)

Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute‐on‐chronic liver failure
por: Campello, Elena, et al.
Publicado: (2021)

Predicting the development of acute kidney injury in liver cirrhosis – an analysis of glomerular filtration rate, proteinuria and kidney injury biomarkers
por: Slack, A J, et al.
Publicado: (2013)

Full-scale model of the ALICE ITS Detector
Publicado: (2004)

ALICE ITS
Publicado: (2003)

ALICE Pixel Ladder (5 chips bump bonded to 1 sensor) mounted on prototype bus
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_bj073jne08qvenf6ka4on8sl3a